| |
Article Title |
Author(s) |
Pages |
|
|
|
Letter from the Editors: Theranostics
We have decided to devote this issue of Seminars to a subject that many of you may have either not heard of, or are just becoming familiar. That subject is theranostics. The concept of theranostics is...
|
Leonard M. Freeman,
M. Donald Blaufox
|
145-146
|
|
|
|
Concepts, Consequences, and Implications of Theranosis
Although the term has been coined recently, the concepts underlying theranosis have been applied in patient care for more than one-half century. However, advanced technologies are used now. Theranosis...
|
Gerald L. DeNardo,
Sally J. DeNardo
|
147-150
|
|
|
|
Paving the Way to Personalized Medicine: Production of Some Promising Theragnostic Radionuclides at Brookhaven National Laboratory
This article reintroduces and reinforces our proposed paradigm that involves specific individual “dual-purpose” radionuclides or radionuclide pairs with emissions suitable for both imaging and therapy...
|
Suresh C. Srivastava
|
151-163
|
|
|
|
Radioiodine: The Classic Theranostic Agent
Radioiodine has the distinction of being the first theranostic agent in our armamentarium. Millennia were required to discover that the agent in orally administered seaweed and its extracts, which had...
|
Edward B. Silberstein
|
164-170
|
|
|
|
Theranostics: Evolution of the Radiopharmaceutical Meta-Iodobenzylguanidine in Endocrine Tumors
Since 1981, meta-iodobenzylguanidine (MIBG), labeled with 131I and later 123I, has become a valuable agent in the diagnosis and therapy of a number of endocrine tumors. Initially, the agent located ph...
|
James C. Sisson,
Gregory A. Yanik
|
171-184
|
|
|
|
FDG for Therapy of Metabolically Active Tumors
18F-2-deoxy-2-fluoro-d-glucose (18F-FDG, later referred to as 19FDG) has been extensively used in diagnostic positron emission tomography (PET) in oncology for many years. FDG is a glucose analog that...
|
Sridivya Jaini,
Ekaterina Dadachova
|
185-189
|
|
|
|
Peptides and Receptors in Image-Guided Therapy: Theranostics for Neuroendocrine Neoplasms
Theranostics of neuroendocrine neoplasms (NENs) based on molecular imaging using receptor positron emission tomography/computed tomography (PET/CT) with 68Ga-labeled somatostatin (SMS) analogs and mol...
|
Richard P. Baum,
Harshad R. Kulkarni,
Cecilia Carreras
|
190-207
|
|
|
|
Accuracy and Precision of Radioactivity Quantification in Nuclear Medicine Images
The ability to reliably quantify activity in nuclear medicine has a number of increasingly important applications. Dosimetry for targeted therapy treatment planning or for approval of new imaging agen...
|
Eric C. Frey,
John L. Humm,
Michael Ljungberg
|
208-218
|
|
